Literature DB >> 20709800

Loss of inducible nitric oxide synthase expression in the mouse renal cell carcinoma cell line RENCA is mediated by microRNA miR-146a.

Christina Perske1, Nitza Lahat, Sharon Sheffy Levin, Haim Bitterman, Bernhard Hemmerlein, Michal Amit Rahat.   

Abstract

Tumor-associated macrophages can potentially kill tumor cells via the high concentrations of nitric oxide (NO) produced by inducible nitric oxide synthase (iNOS); however, tumor-associated macrophages actually support tumor growth, as they are skewed toward M2 activation, which is characterized by low amounts of NO production and is proangiogenic. We show that the mouse renal cell carcinoma cell line, RENCA, which, on stimulation, expresses high levels of iNOS mRNA, loses its ability to express the iNOS protein. This effect is mediated by the microRNA miR-146a, as inhibition of RENCA cells with anti-miR- 146a restores iNOS expression and NO production (4.8 ± 0.4 versus 0.3 ± 0.1 μmol/L in uninhibited cells, P < 0.001). In vivo, RENCA tumor cells do not stain for iNOS, while infiltrating tumor-associated macrophages showed intense staining, and both cell types expressed iNOS mRNA. Restoring iNOS protein expression in RENCA cells using anti-miR-146a increases macrophage-induced death of RENCA cells by 73% (P < 0.01) in vitro and prevents tumor growth in vivo. These results suggest that, in addition to NO production by macrophages, tumor cells must produce NO to induce their own deaths, and some tumor cells may use miR-146a to reduce or abolish endogenous NO production to escape macrophage-mediated cell death. Thus, inhibiting miR-146a may render these tumor cells susceptible to therapeutic strategies, such as adoptive transfer of M1-activated macrophages.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709800      PMCID: PMC2947298          DOI: 10.2353/ajpath.2010.091111

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

1.  Loss of mir-146a function in hormone-refractory prostate cancer.

Authors:  Shi-Lung Lin; Angela Chiang; Donald Chang; Shao-Yao Ying
Journal:  RNA       Date:  2008-01-03       Impact factor: 4.942

Review 2.  MicroRNAs: new regulators of immune cell development and function.

Authors:  David Baltimore; Mark P Boldin; Ryan M O'Connell; Dinesh S Rao; Konstantin D Taganov
Journal:  Nat Immunol       Date:  2008-08       Impact factor: 25.606

3.  Suppression of tumorigenicity and metastasis of human renal carcinoma cells by infection with retroviral vectors harboring the murine inducible nitric oxide synthase gene.

Authors:  S H Juang; K Xie; L Xu; Q Shi; Y Wang; J Yoneda; I J Fidler
Journal:  Hum Gene Ther       Date:  1998-04-10       Impact factor: 5.695

4.  Expression of cyclooxygenase-2 and inducible nitric oxide synthase in ovarian surface epithelial carcinomas: is there any correlation with angiogenesis or clinicopathologic parameters?

Authors:  E Ozel; H E Peştereli; T Simşek; G Erdoğan; F S Karaveli
Journal:  Int J Gynecol Cancer       Date:  2006 Mar-Apr       Impact factor: 3.437

Review 5.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

Authors:  O A Kent; J T Mendell
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

6.  NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses.

Authors:  Konstantin D Taganov; Mark P Boldin; Kuang-Jung Chang; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-02       Impact factor: 11.205

Review 7.  Post-translational modifications induced by nitric oxide (NO): implication in cancer cells apoptosis.

Authors:  Lissbeth Leon; Jean-François Jeannin; Ali Bettaieb
Journal:  Nitric Oxide       Date:  2008-04-24       Impact factor: 4.427

Review 8.  Nitric oxide, apoptosis and macrophage polarization during tumor progression.

Authors:  Andreas Weigert; Bernhard Brüne
Journal:  Nitric Oxide       Date:  2008-04-29       Impact factor: 4.427

Review 9.  iNOS as a therapeutic target for treatment of human tumors.

Authors:  Brian Fitzpatrick; Manal Mehibel; Rachel L Cowen; Ian J Stratford
Journal:  Nitric Oxide       Date:  2008-05-13       Impact factor: 4.427

Review 10.  Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives.

Authors:  R Andreesen; B Hennemann; S W Krause
Journal:  J Leukoc Biol       Date:  1998-10       Impact factor: 4.962

View more
  17 in total

Review 1.  [History and perspectives of the monocyte-macrophage system].

Authors:  H-J Radzun
Journal:  Pathologe       Date:  2015-09       Impact factor: 1.011

2.  Inhibition of tumor growth and metastasis by EMMPRIN multiple antigenic peptide (MAP) vaccination is mediated by immune modulation.

Authors:  Elina Simanovich; Vera Brod; Maya M Rahat; Ella Drazdov; Miriam Walter; Jivan Shakya; Michal A Rahat
Journal:  Oncoimmunology       Date:  2016-11-29       Impact factor: 8.110

3.  An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression.

Authors:  Miriam Walter; Elina Simanovich; Vera Brod; Nitza Lahat; Haim Bitterman; Michal A Rahat
Journal:  Oncoimmunology       Date:  2015-08-28       Impact factor: 8.110

Review 4.  The regulation and function of microRNAs in kidney diseases.

Authors:  Qingqing Wei; Qing-Sheng Mi; Zheng Dong
Journal:  IUBMB Life       Date:  2013-07       Impact factor: 3.885

Review 5.  MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response.

Authors:  Kobina Essandoh; Yutian Li; Jiuzhou Huo; Guo-Chang Fan
Journal:  Shock       Date:  2016-08       Impact factor: 3.454

6.  NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.

Authors:  Haifeng Zhu; Deeksha Vishwamitra; Choladda V Curry; Roxsan Manshouri; Lixia Diao; Aarish Khan; Hesham M Amin
Journal:  J Pathol       Date:  2013-03-14       Impact factor: 7.996

7.  Later phase cardioprotection of ischemic post-conditioning against ischemia/reperfusion injury depends on iNOS and PI3K-Akt pathway.

Authors:  Gongming Wang; Xin Li; Hong Wang; Yan Wang; Ligong Zhang; Le Zhang; Bei Liu; Mengyuan Zhang
Journal:  Am J Transl Res       Date:  2015-12-15       Impact factor: 4.060

8.  Function of miR-146a-5p in Tumor Cells As a Regulatory Switch between Cell Death and Angiogenesis: Macrophage Therapy Revisited.

Authors:  Elina Simanovich; Vera Brod; Maya M Rahat; Michal A Rahat
Journal:  Front Immunol       Date:  2018-01-05       Impact factor: 7.561

9.  Macrophage-tumor cell interactions regulate the function of nitric oxide.

Authors:  Michal A Rahat; Bernhard Hemmerlein
Journal:  Front Physiol       Date:  2013-06-18       Impact factor: 4.566

10.  Tumor cell-macrophage interactions increase angiogenesis through secretion of EMMPRIN.

Authors:  Bat-Chen Amit-Cohen; Maya M Rahat; Michal A Rahat
Journal:  Front Physiol       Date:  2013-07-12       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.